Plain-English translation of NCT06400472 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Neoplasms research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human study testing a new medication called , which is designed to target and attack cancer cells that express a specific protein called folate receptor alpha. The trial will evaluate whether this treatment is safe, well-tolerated, and effective in people with several types of advanced solid tumors. The study will take place in two stages: first, researchers will test increasing doses to find the right amount, and then they will expand to larger groups to confirm how well the medication works.
Many advanced cancers are difficult to treat and current options may not work for everyone or may cause serious side effects. This medication was designed with a new approach—using an antibody to carry a cancer-fighting drug directly to tumor cells—in hopes of being more effective and potentially gentler than standard treatments.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication on a regular schedule at a clinic or hospital. Depending on which group you are assigned to, you may receive the medication alone or in combination with other established cancer treatments. The study will last up to approximately 4 years, during which you will have regular visits for blood tests, scans, and check-ups to monitor how you are responding and watch for side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States